Immunological mechanisms of interleukin-2 (IL-2) treatment in HIV/AIDS disease

Current Molecular Pharmacology

Volumn 2, Issue 1, 2009, Pages 40-45

  Tincati, C ^a   d'Arminio Monforte, A ^a   Marchetti, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Immune reconstitution; Immunotherapy; Interleukin 2

Indexed keywords

INTERLEUKIN 2; ANTIVIRUS AGENT; INTERLEUKIN 7;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL DEATH; CELL GROWTH; DRUG ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNITY; IMMUNOTHERAPY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; BLOOD; IMMUNOLOGY; METABOLISM; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; INTERLEUKIN-7;

EID: 77449158542     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467210902010040     Document Type: Article

References (63)

1. Kasakura, S.; Lownstein, L. A factor stimulating DNA synthesis derived from the medium of leukocyte cultures. Nature 1965, 208, 794-795.
2. Morgan, D. A.; Ruscitti, F. W.; Gallo, R. C. Selective in vitro growth of lymphocytes from hormonal bone marrows. Science 1976, 193, 1700-1800.
3. Curfs, J. H.; Meis J. F.; Hoogkamp-Korstanje, J. A. A. A primer on cytokines: sources, receptor, effects, and inducers. Clin. Microbiol. Rev. 1997, 742-780.
4. Kinter, A. Interleukin-2 and human immunodeficiency virus infection: pathogenic mechanism and potential for immunologic enhancement. Immunol. Res. 1996, 15, 1-15.
5. Moll, M.; Snyder-Cappione, J.; Spotts, G.; Hecht, F. M.; Sandberg, J. K.; Nixon, D. F. Expansion of CD1d-restricted NKT cells in patients with primary HIV-1 infection treated with interleukin-2. Blood 2006, 107, 3081-3083.
6. Lane, H. C.; Fauci, A. S. Immunologic abnormalities in the acquired immuno deficiency syndrome. Annu. Rev. Immunol. 1985, 3, 477-500.
7. Giorgi, J. V.; Nishanian, P. G.; Schmid, I.; Hultin, L. E.; Cheng, H. L.; Detels, R. Selective alterations in immunoregulatory lymphocyte subsets in early HIV (human T-lymphotropic virus type III/lymphadenopathy associated virus) infection. J. Clin. Immunol. 1987, 7, 140-150.
8. Miedema, F.; Petit, A. J.; Terpstra, F. G.; Schattenkerk, J. K.; de Wolf, F.; Al, B. J.; Roos, M.; Lange, J. M.; Danner, S. A.; Goudsmit, J. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J. Clin. Invest. 1988, 82, 1908-1914.
9. Clerici, M.; Stocks, N. I.; Zajac, R. A.; Boswell, R. N.; Bernstein, D. C.; Mann, D. L.; Shearer, G. M.; Berzofsky, J. A. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature 1989, 339, 383-385.
10. Lucey, D. R.; Hensley, R. E.; Ward, W. W.; Butzin, C. A.; Boswell, R. N. CD4+ monocyte counts in persons with HIV-1 infection: an early increase is followed by a progressive decline. J. Acquir Immune Defic. Syndr. 1991, 4, 24-30.
11. Dolan, M. J.; Clerici, M.; Blatt, S. P.; Hendrix, C. W.; Melcher, G. P.; Boswell, R. N.; Freeman, T. M.; Ward, W.; Hensley, R.; Shearer, G. M. In vitro T-cell function, delayed-type hypersensitivity skin testing, and CD4+ T-cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J. Infect. Dis. 1995, 172, 79-87.
12. Pereyra, F.; Addo, M. M.; Kaufmann, D. E.; Liu, Y.; Miura, T.; Rathod, A.; Baker, B.; Trocha, A.; Rosenberg, R.; Mackey, E.; Ueda, P.; Lu, Z.; Cohen, D.; Wrin, T.; Petropoulos C. J.; Rosenberg, E. S.; Walker, B. D. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 2008, 197, 563-571.
13. Kannanganat, S.; Kapogiannis, B. G.; Ibegu, C.; Chennareddi, L; Goepfert, P.; Robinson, H. L.; Lennox, J.; Amara, R. R. Human immunodeficiency virus type 1 controllers but noncontrollers maintain CD4 T-cells coexpressing three cytokines. J. Virol. 2007, 81, 12071-12076.
14. Potter, S. J.; Lacabaratz, C.; Lambotte, O.; Perez-Patrigeon, S.; Vingert, B.; Sinet, M.; Colle, J. H.; Urrutia, A.; Scott-Alagara, D.; Boufassa, F.; Del-fraissy, J. F.; Theze, J.; Venet, A.; Chakrabarti, L. A. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J. Virol. 2007, 81, 13904-13915.
15. Kilby, J.M.; Bucy, R. P.; Mildvan, D.; Fischl, M.; Santana-Bagur, J.; lennox, J.; Pilcher, C.; Zolopa, A.; Lawrence, J.; Pollard, R. B.; Habib, R. E.; Sahner, D.; Fox, L.; Aga, E.; Bosch, R. J.; Mitsuyasu, R. Adult AIDS Clinical Trials Group A5024 Protocol Team. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). J. Infect. Dis. 2006, 194, 1672-1676.
16. Haas, D. W.; Geraghty, D. E.; Andersen, J.; Mar, J.; Motsinger, A. A.; D'Aquila, R.T.; Unutmaz, D.; Benson, C. A.; Ritchie, M. D.; Landay, A. AIDS Clinical Trials Group. Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study. J. Infect. Dis. 2006, 194, 1098-1107.
17. Henry, K.; Katzenstein, D.; Cherng, D. W.; Valdez, H.; Powderly, W.; Vargas, M. B.; Jahed, N. C.; Jacobson, J. M.; Myers, L. S.; Schmitz, J. L.; Winters, M.; Tebas, P. A5102 Study Team of the AIDS Clinical Trials Group. A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interrupation following antiretroviral therapy +/-interleukin 2: results of ACTG A5102. J. Acquir Immune Defic. Syndr. 2006, 42, 140-148.
18. Levy, Y.; Gahery-Segard, H.; Durier, C.; Lascaux, A. S.; Goujard, C.; Meiffredy, V.; Rouzioux, C.; El Habib, R.; Beumont-Mauviel, M.; Guillet, J. G.; Delfraissy, J. F.; Abouker, J. P. ANRS 093 Study Group. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 2005, 3, 279-286.
19. Vogler, M. A.; Teppler, H.; Gelman, R.; Valentine, F.; Lederman, M. M.; Pomerantz, R. J.; Pollard, R. B., Cherng, D. W.; Gonzalez, C. J.; Squires, K. E.; Frank, I.; Mildvan, D.; Mahon, L. F.; Schock, B. AIDS Clinical Trilas Group 248 Study Team. Daily low-dose subcutaneous interleukin-2 added to single-or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248). J. Acquir Immune Defic. Syndr. 2004, 1, 576-587.
20. Chun, T. W.; Engel, D.; Mizell, S. B.; Ehler, L. A.; Fauci, A. S. Induction of HIV-1 replication in latently infected CD4+ T-cells using a combination of cytokines. J. Exp. Med. 1998, 188, 83-91.
21. 3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 Trial). Antivir. Ther. 2003, 8, 233-237.
22. Kovacs, J. A.; Baseler, M.; Dewar, R. J.; Vogel, S.; Davey, R. T. Jr.; Falloon, J.; Polis, M. A.; Walker, R. E.; Stevens, R.; Salzman N. P. Increases in CD4 T-lympocytes with intermittent course of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N. Engl. J. Med. 1995, 332, 567-575.
23. Davey, R. T. Jr.; Chaitt, D. G.; Piscitelli, S. C.; Wells, M.; Kovacs, J. A.; Walker, R. E.; Falloon, J.; Polis, M. A.; Metcalf, J. A.; Masur, H.; Fyfe, G.; Lane, H. C. Subcutaneous administratiom of interleukin-2 in human immunodeficiency virus type 1-infected persons. J. Infect. Dis. 1997, 175, 781-189.
24. Mitsuyasu, R.; Gelman, R.; Chern D.W.; Landay, A.; Fahey, J.; Reichman, R.; Erice, A.; Bucy, R. P.; Kilby, J. M.; Lederman, M. M.; Hamilton, C. D.; Lertora, J.; White, B. L.; Tebas, P.; Duliege, A. M.; Pollard, R. B. AIDS Clinical Trials Group 328 Study Team. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. Arch. Intern. Med. 2007, 167, 597-605.
25. Go, R.; Steigbiel, R. Interleukin 2 and HIV RNA levels. Arch. Intern. Med. 2007, 167, 2144-2145.
26. Bagby, G.; Heinrich, M. In Hematology Basic Principles and Practice: Growth factors, cytokines, and the control of hematopoiesis; Churchill Livingstone: Philadelphia, PA, USA, 2000, pp. 154-202.
27. Natarajan, V.; Lempicki, R. A.; Sereti, I.; Badralmaa, Y.; Adelsberger, J. W.; Metcalf, J. A.; Prieto, D. A.; Stevens, R.; Baseler, M. W.; Kovacs, J. A.; Lane, H. C. Increased peripheral expansion of naive CD4+ T-cells in vivo after IL-2 treatment of patients with HIV infection. Proc. Natl. Acad. Sci. USA 2002, 99, 10712-10717.
28. Sereti, I.; Herpin, B.; Metcalf, J. A.; Stevens, R.; Baseler, M. W.; Hallahan, C. W.; Kovacs, J. A.; Davey, R. T.; Lane, H. C. CD4 T-cell expansions are associated with increased apoptosis rates of T-lymphocytes during IL-2 cycles in HIV infected patients. AIDS 2001, 15, 1765-1775.
29. De Paoli, P.; Zanussi, S.; Simonelli, C.; Bortolin, M. T.; D'Andrea, M.; Crepaldi, C.; Talamini, R.; Comar, M.; Giacca, M.; Tirelli, U. Effects of sub-cutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects. J. Clin. Invest. 1997, 100, 2737-2743.
30. Hengge, U. R.; Borchard, C.; Esser, S.; Schroder, M.; Mirmohammadsadegh, A.; Goos, M. Lymphocytes proliferate in blood and lymph nodes following interleukin-2 therapy in addition to highly active antiretroviral therapy. AIDS 2002, 16, 151-160.
31. Grossman, Z.; Meier-Schellersheim, M.; Sousa, A. E.; Victorino, R. M.; Paul, W. E. CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause? Nat. Med. 2002, 8, 319-323.
32. Douek, D.; Picker, L.; Koup, R. T-cell dynamics in HIV-1 infection. Annu. Rev. Immunol. 2003, 21, 265-304.
33. Marchetti, G.; Meroni, L.; Varchetta, S.; Terzieva, V.; Bandera, A.; Manganaro, D.; Molteni, C.; Trabattoni, D.; Fossati, S.; Clerici, M.; Galli, M.; Moroni, M.; Franzetti, F.; Gori, A. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J. Infect. Dis. 2002, 186, 606-616.
34. Sereti, I.; Martinez-Wilson, H.; Metcalf, J. A.; Baseler, M. W.; Hallahan, C. W.; Hahn, B.; Hengel, R. L.; Davey, R. T.; Kovacs, J. A.; Lane, H. C. Longterm effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T-cells. Blood 2002, 100, 2159-2167.
35. Sereti, I.; Anthony, K. B.; Martinez-Wilson, H.; Lempicki, R.; Adelsberger, J.; Metcalf, J. A.; Hallahan, C. W.; Follmann, D.; Davey, R. T.; Kovacs, J. A.; Lane, H. C. IL-2-induced T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 2004, 104, 775-780.
36. Marchetti, G.; Franzetti, F.; Gori, A. Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap? J. Antimicrob. Chemother. 2005, 55, 401-409.
37. Kovacs, J. A.; Lempicki, R. A.; Sidorov, I. A.; Adelsberger, J. W.; Sereti, I.; Sachau, W.; Kelly, G.; Metcalf, J. A.; Davey, R. T. Jr.; Falloon, J.; Polis, M. A.; Tavel, J.; Stevens, R.; Lambert, L.; Hosack, D. A.; Bosche, M.; Issaq, H. J.; Fox, S.D.; Leitman, S.; Baseler, M. W.; Masur, H.; Di Mascio, M.; Dimitrov, D. S.; Lane, H. C. Induction of prolonged survival of CD4+ Tlymphocytes by intermittent IL-2 therapy in HIV-infected patients. J. Clin. Invest. 2005, 115, 2139-2148.
38. Marchetti, G.; Meroni, L.; Molteni, C.; Taskaris, G.; Gazzola, L.; Galli, M.; Clerici, M.; Moroni, M.; Franzetti, F.; Gori, A. IL-7/IL-7 receptor system regulation following IL-2 immunotherapy in HIV-infected patients. Antivir. Ther. 2004, 9, 447-452.
39. Marchetti, G.; Meroni, L.; Molteni, C.; Bandera, A.; Franzetti, F.; Galli, M.; Moroni, M.; Clerici, M.; Gori, A. Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T-cell dynamics. AIDS 2004, 18, 211-6.
40. Lenardo, M.; Chan, K. M.; Hornung, F.; McFarland, H.; Siegel, R.; Wang, J.; Zheng, L. Mature T-lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol. 1999, 17, 221-253.
41. Ku, C. C.; Murakami, M.; Sakamoto, A.; Kappler, J.; Marrack, P. Control of homeostasis of CD8+ memory T-cells by opposing cytokines. Science 2000, 288, 675-678.
42. Caggiari, L.; Zanussi, S.; Bortolin, M. T.; D' Andrea, M.; Nasti, G.; Simonelli, C.; Tirelli, U.; De Paoli, P. Effects of therapy with highly active antiretroviral therapy (HAART) and IL-2 on CD4+ and CD8+ lymphocyte apoptosis in HIV+ patients. Clin. Exp. Immunol. 2000, 120, 101-106.
43. Pandolci, F.; Pierdominici, M.; Marziali, M.; Livia Bernardi, M.; Antonelli, G.; Galati, V.; D'Offizi, G.; Aiuti, F. Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART. Clin. Immunol. 2000, 94, 153-159.
44. Paiardini, M.; Galati, D.; Cervasi, B.; Cannavo, G.; Galluzzi, L.; Montoni, M.; Guetard, D.; Magnani, M.; Piedimonte, G.; Silvestri, G. Exogenous interleukin-2 administration corrects the cell cycle perturbation of lymphocytes from human immunodeficiency virus-infected individuals. J. Virol. 2001, 75, 10843-10855.
45. ESPRIT Research Group; Fox, Z.; Antunes, F.; Davey, R.; Gazzard, B.; Kilmas, N.; Labriola, A.; Losso, M.; Necton, J. D.; Phillips, A. N.; Ruxrungtham, K.; Staszewski, S.; Weiss, L.; Lundgren, J. D. Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count >or=300 cells/microL who were assigned to 7.5 MIU interleukin-2. HIV Med. 2007, 8, 112-123.
46. Sereti, I.; Sklar, P.; Ramchandani, M. S.; Read, S. W.; Aggarwal, V.; Imamichi, H.; Natarajan, V.; Metcalf, J. A.; Kovacs, J. A.; Tavel, J.; Davey, R. T.; Dersimonian, R.; Lane, H. C. CD4+ T-cell responses to interleukin-2 adminsitration in HIV-infected patients are directly related to the baseline level of immune activation. J. Infect. Dis. 2007, 196, 677-683.
47. Douek, D. C.; Brenchley, J. M.; Betts, M. R.; Ambrozak, D. R.; Hill, B. J.; Okamoto, Y.; Casazza, J. P.; Kuruppu, J.; Kunstman, K.; Wolinsky, S.; Grossman, Z.; Dybul, M.; Oxenius, A.; Price, D. A.; Connors, M.; Koup, R. A. HIV preferentially infects HIV-specific CD4+ T-cells. Nature 2002, 417, 95-98.
48. Kovacs, J. A.; Vogel, S.; Metcalf, J. A.; Baseler, M.; Stevens, R.; Adelsberger, J.; Lempicki, R.; Hengel, R. L.; Sereti, I.; Lambert, L.; Dewar, R. L.; Davey, R. T. Jr.; Walker, R. E.; Falloon, J.; Polis, M. A.; Masur, H.; Lane, H. C. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy. Eur. J. Immunol. 2001, 31, 1351-1360.
49. Davey, R. T. Jr.; Chaitt, D. G.; Albert, J. M.; Piscitelli, S. C.; Kovacs, J. A.; Walker, R. E.; Falloon, J.; Polis, M. A.; Metcalf, J. A.; Masur, H.; Dewar, R.; Baseler, M.; Fyfe, G.; Giedlin, M. A.; Lane, H. C. A randomized trial of high-versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J. Infect. Dis. 1999, 179, 849-858.
50. De Paoli, P.; Bortolin, M. T.; Zanussi, S.; Monzoni, A.; Pratesi, C.; Giacca, M. Changes in thymic function in HIV-positive patients treated with highly active antiretroviral therapy and interleukin-2. Clin. Exp. Immunol. 2001, 125, 440-446.
51. Carcelain, G.; Saint-Mezard, P.; Altes, H. K.; Tubiana, R.; Grenot, P.; Rabian, C.; de Boer, R.; Katlama, C.; Debrè, P.; Autran, B. IL-2 therapy and thymic production of naive CD4 T-cells in HIV-infected patients with severe CD4 lymphopenia. AIDS 2003, 17, 841-850.
52. Furtado, G. C.; Curotto de Lafaille, M. A.; Kutchukhidze, N.; Lafaille, J. J. Interleukin 2 signaling is required for CD4(+) regulatory T-cell function. J. Exp. Med. 2002, 196, 851-857.
53. Nelson, B. H. IL-2, regulatory T-cells, and tolerance. J. Immunol. 2004, 172, 3983-3988.
54. Kinter, A. L.; Hennessey, M.; Bell, A.; Kern, S.; Lin, Y.; Daucher, M.; Planta, M.; McGlaughlin, M.; Jackson, R.; Ziegler, S. F.; Fauci, A. S. CD25(+)CD4(+) regulatory T-cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T-cell immune responses in vitro and are associated with favorable clinical markers of disease status. J. Exp. Med. 2004, 200, 331-343.
55. Sereti, I.; Imamichi, H.; Natarajan, V.; Imamichi, T.; Ramchandani, M.S.; Badralmaa, Y.; Berg, S. C.; Metcalf, J. A.; Hahn, B. K.; Shen, J. M.; Powers, A.; Davey, R. T.; Kovacs, J. A.; Shevach, E. M.; Lane, H. C. In vivo expansion of CD4CD45RO-CD25 T-cells epressing foxP3 in IL-2-treated HIV-infected patients. J. Clin. Invest. 2005, 115, 1839-1847.
56. Fry, T. J.; Connick, E.; Falloon, J.; Lederman, M. M.; Liewehr, D. J.; Spritzler, J.; Steinberg, S. M.; Wood, L. V.; Yarchoan, R.; Zuckerman, J.; Landay, A.; Mackall, C. L. A potential role for interleukin-7 in T-cell homeostasis. Blood 2001, 97, 2983-2990.
57. Ruiz-Mateos, E.; de la Rosa, R.; Franco, J. M.; Martinez-Moya, M.; Rubio, A.; Soriano, N.; Sanchez-Quijano, A.; Lissen, E.; Leal, M. Endogenous IL-7 is associated with increased thymic volume in adult HIV-infected patients under highly active antiretroviral therapy. AIDS 2003, 17, 947-954.
58. Kovacs, J. A.; Vogel, S.; Albert, J. M.; Falloon, J.; Davey, R. T. Jr.; Walker, R. E.; Polis, M. A.; Spooner, K.; Metcalf, J. A.; Baseler, M.; Fyfe, G.; Lane, H. C. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 1996, 335, 1350-1356.
59. Napolitano, L. A.; Grant, R. M.; Deeks, S. G.; Schmidt, D.; De Rosa, S. C.; Herzenberg, L. A.; Herndier, B. G.; Andersson, J.; McCune, J. M. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat. Med. 2001, 7, 73-79.
60. Llano, A.; Barretina, J.; Gutiérrez, A.; Blanco, J.; Cabrera, C.; Clotet, B.; Esté, J. A. Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals. J. Virol. 2001, 75, 10319-10325.
61. Mastroianni, C. M.; Forcina, G.; d'Ettorre, G.; Lichtner, M.; Mengoni, F.; D'Agostino, C.; Vullo, V. Circulating levels of interleukin-7 in antiretroviralnaïve and highly active antiretroviral therapy-treated HIV-infected patients. HIV Clin. Trials 2001, 2, 108-112.
62. Schluns, K. S.; Kieper, W. C.; Jameson, S. C.; Lefrançois, L. Interleukin-7 mediates the homeostasis of naïve and memory CD8 T-cells in vivo. Nat. Immunol. 2000, 1, 426-432.
63. Read, S. W.; Higgins, J.; Metcalf, J. A.; Stevens, R. A.; Rupert, A.; Nason, M. C.; Lane, H. C.; Sereti, I. Decreased CD127 expression on T-Cells in HIV-1-infected adults receiving antiretroviral therapy with or without intermittent IL-2 therapy. J. Acquir Immune Defic. Syndr. 2006, 42, 537-544.